Lancet Oncol: Navusan anti-new assisted immunochemotherapy greatly improves the prognostics of small cell lung cancer.

Most patients with non-small cell lung cancer (NSCLC) are diagnosed with end-stage, i.e. local late stage.
study aims to assess the anti-tumor activity and safety of new auxiliary immunotherapy in patients with removable stage IIIA NSCLC.
the trial is an open-label, one-arm Phase 2 trial conducted in 18 hospitals, recruiting untreated, surgically removable IIIA NSCLC patients over the age of 18 for three courses of new complementary treatment: yew alcohol (200 mg/m2), capratin (6 mg/mL.min) and navu monoantigen (360 mg), 1st day of dosing, 1 course/21 days;
end point is 24 months of progress-free survival.
April 26, 2017 - August 25, 2018, 51 patients were screened, 46 of them were included, and new complementary treatments were provided.
as of January 31, 2020, the middle followed up for 24 months (IQR 21.4-28.1) and 35 of the 41 patients with tumor removal had no progression.
24 months, the progress-free survival rate was 77.1% (95% CI 59.9-87.7).
43 (93%) patients experienced treatment-related adverse reactions during the new complementary treatment period, of which 14 had treatment-related adverse reactions of level 3 and above, but none of the adverse reactions were associated with delayed surgery or death.
most common level 3 and above treatment adverse reactions were elevated lipase (3 cases (7 per cent) and decreased fever-neutral granulocytes (3 cases (7 per cent).
, the study supported the addition of the new auxiliary drug narcostin to platinum chemotherapy in patients with removable STAGE IIIA NSCLC.
new complementary immunotherapy is expected to change localised advanced lung cancer from a potentially fatal disease to a curable one.
.